Bioscience Department, Rocky Vista University College of Osteopathic Medicine, Ivins, UT 84738, USA.
Medicina (Kaunas). 2022 May 5;58(5):637. doi: 10.3390/medicina58050637.
Female sexual dysfunction (FSD) in hypertension has been less studied than male sexual dysfunction, and antihypertensive agents' impact on female sexual function is not defined. In this review, randomized double-blind clinical trials and cross-sectional studies related to female sexual function in hypertension were analyzed from 1991 to 2021. FSD appeared to be higher in hypertensive women than in normotensive women. Beta-blockers are the only antihypertensive agents with relatively strong evidence of damaging the female sexual function. Angiotensin receptor blockers (ARB) are relatively beneficial to female sexual function. To treat FSD in the presence of hypertension, controlling blood pressure is key, and the administration of angiotensin receptor blockers is preferred. In addition to controlling blood pressure, for premenopausal women, flibanserin and bremelanotide can be tried, while ospemifene and hormone supplements are preferred for postmenopausal women.
女性性功能障碍（FSD）在高血压中的研究不如男性性功能障碍多，而且降压药物对女性性功能的影响尚未确定。在这篇综述中，分析了 1991 年至 2021 年间与高血压女性性功能相关的随机双盲临床试验和横断面研究。高血压女性的 FSD 似乎高于血压正常女性。β受体阻滞剂是唯一具有相对较强证据表明损害女性性功能的降压药物。血管紧张素受体阻滞剂（ARB）对女性性功能相对有益。在存在高血压的情况下治疗 FSD，控制血压是关键，首选血管紧张素受体阻滞剂。除了控制血压外，对于绝经前女性，可以尝试使用氟班色林和布美诺肽，而对于绝经后女性，则首选奥昔布宁和激素补充剂。
